Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF 84 Intrinsic Value: Projected FCF is $9.66 as of Sep. 16, 2026. GuruFocus rates SUSRF with a GF Score™ of 84/100 and a GF Value™ of $19.53 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 347 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 79.25% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Surgical Science Sweden AB's Intrinsic Value: Projected FCF or its related term are showing as below:
SUSRF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.33 Med: 1.74 Max: 4.88
Current: 0.54
During the past 11 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Surgical Science Sweden AB was 4.88. The lowest was 0.33. And the median was 1.74.
SUSRF's Price-to-Projected-FCF is ranked better than 79.25% of 347
companies
in the Healthcare Providers & Services industry
Industry Median: 1.05
vs SUSRF: 0.54
Surgical Science Sweden AB (OTCPK:SUSRF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Surgical Science Sweden AB's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
5.20
/
10.446800809404
=
0.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Intrinsic Value: Projected FCF Related Terms
Surgical Science Sweden AB Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Surgical Science Sweden AB's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Intrinsic Value: Projected FCF Chart
SUSRF vs VEEV, BTSG, TEM: Intrinsic Value: Projected FCF Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Price-to-Projected-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Price-to-Projected-FCF falls into.
Surgical Science Sweden AB Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $9.66 mean?
Surgical Science Sweden AB (SUSRF) has a Intrinsic Value: Projected FCF of $9.66 as of Sep. 16, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Surgical Science Sweden AB and its competitors. According to the industry distribution chart, Surgical Science Sweden AB ranks #72 out of 347 companies in the Healthcare Providers & Services industry, placing it in the top 20.7%.
Is Surgical Science Sweden AB's Intrinsic Value: Projected FCF too high?
Surgical Science Sweden AB's current Intrinsic Value: Projected FCF is $9.66. The Healthcare Providers & Services industry median Intrinsic Value: Projected FCF is 1.05. Surgical Science Sweden AB's value of $9.66 is 820% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #72 out of 347 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Surgical Science Sweden AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Intrinsic Value: Projected FCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #72 out of 347 companies for Intrinsic Value: Projected FCF. This places Surgical Science Sweden AB in the top 21% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.05. Surgical Science Sweden AB's value of $9.66 is 820% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Healthcare Providers & Services company?
The median Intrinsic Value: Projected FCF among Healthcare Providers & Services companies is 1.05, based on 347 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Intrinsic Value: Projected FCF of $9.66 is 820% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Intrinsic Value: Projected FCF is 1.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Intrinsic Value: Projected FCF is $9.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $19.53, compared to a current price of $5.20 — trading 73.4% below its estimated fair value. The current Intrinsic Value: Projected FCF is $9.66 and 820% above the Healthcare Providers & Services industry median of 1.05. Surgical Science Sweden AB's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Intrinsic Value: Projected FCF is $9.66 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $5.20 is trading 73.4% below its estimated GF Value™ of $19.53.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Intrinsic Value: Projected FCF: $9.66
GF Value™: $19.53 vs. price of $5.20 (73.4% below fair value)
Industry Position: 820% above the Healthcare Providers & Services median (#72 of 347)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
84GF Score
Get the complete analysis for SUSRF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
